Emerging drugs for moderate-to-severe psoriasis

Author： Magliocco Melissa A  

Publisher： Informa Healthcare

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.10, Iss.1, 2005-02, pp. : 35-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ustekinumab useful for moderate-to-severe plaque psoriasis

By  

Inpharma, Vol. 1, Iss. 1624, 2008-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of moderate-to-severe psoriasis treatment

By Miller Drew W   Feldman Steven R  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 157-167

Informa Healthcare

Access to resources Recommend Favorite

Treatment failure rate, costs high in moderate-to-severe psoriasis

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 473, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Treatment failure rate, costs high in moderate-to-severe psoriasis

By  

Inpharma, Vol. 1, Iss. 1479, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Etanercept shows efficacy in treating patients with moderate-to-severe plaque psoriasis

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite